Souza, Isis Nem de Oliveira, Roychaudhuri, Robin, de Belleroche, Jacqueline, and Mothet, Jean-Pierre
Trends in Molecular Medicine. Dec2023, Vol. 29 Issue 12, p1014-1028. 15p.
BRAIN diseases, ALZHEIMER'S disease, AMYOTROPHIC lateral sclerosis, CENTRAL nervous system, ENDOCRINE system, and CYSTEINE
d -Amino acids (d- AAs) form a novel class of vital signaling molecules that control brain homeostasis. Abnormal d -AAs levels in biofluids and tissues occur in various brain disorders. d -AAs can be used as biomarkers for disease diagnosis, prognosis, and treatment monitoring. d -AA signaling and metabolic pathways are promising druggable targets for chronic and acute neuropathologies. Free d -amino acids (d -AAs) are emerging as a novel and important class of signaling molecules in many organs, including the brain and endocrine systems. There has been considerable progress in our understanding of the fundamental roles of these atypical messengers, with increasingly recognized implications in a wide range of neuropathologies, including schizophrenia (SCZ), epilepsy, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), substance abuse, and chronic pain, among others. Research has enabled the discovery that d -serine, d -aspartate and more recently d -cysteine are essential for the healthy development and function of the central nervous system (CNS). We discuss recent progress that has profoundly transformed our vision of numerous physiological processes but has also shown how d -AAs are now offering therapeutic promise in clinical settings for several human diseases. [ABSTRACT FROM AUTHOR]
- Full text View on content provider's site